Clinical study of the correlation between cholesterol absorption and coronary risk factors or arteriosclerotic diseases, and of the clinical significance of the controlling cholesterol absorption.

Clinical study of the correlation between cholesterol absorption and coronary risk factors or arteriosclerotic diseases, and of the clinical significance of the controlling cholesterol absorption. - Clinical study of the inhibition of cholesterol absorption.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001718

Enrollment

200

Registered

2009-02-23

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Interventions

Twelve weeks Ezetimibe administration to the patients with hypercholesterolemia without statins. Twelve weeks Ezetimibe administration to the patients with hypercholesterolemia taking statins.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Serum LDL-C level is higher than the management targeted value in Japan atherosclerosis society guidelines for prevention of atherosclerotic cardiovascular diseases 2007.

Exclusion criteria

Exclusion criteria: Severe liver or renal dysfunction. The patient using fibrate or insulin. Secondary hypercholesterolemia. Pregnant women.

Design outcomes

Primary

Measure	Time frame
1. Association between the cholesterol asynthesis/absorption markers before Ezetimibe administration and coronary risk factors or arteriosclerotic diseases. 2. Amount or rate of changes in LDL-C after Ezetimibe administration. 3. Correlation between the amount or rate of changes in LDL-C after Ezetimibe administration and the cholesterol synthesis/absorption markers.	—

Secondary

Measure	Time frame
Changes of RLP-cholesterol, HDL-C, triglyceride, insulin, plasma glucose, HbA1c, and hs-CRP.	—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

Miyazaki Medical College, University of Miyazaki Neurology, Respirology, Endocrinology and Metabolism

intron@med.miyazaki-u.ac.jp0985-85-2965

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026